Part D Cost Estimate Drops To $373 Bil. Over 10 Years
This article was originally published in The Pink Sheet Daily
CMS attributes the 41 percent drop from the original $634 billion estimate in part to better-than-anticipated drug price negotiations by Part D plans and a decline in drug cost trend.
You may also be interested in...
The pace of those taking advantage of the 50% discount on brand drugs provided by manufacturers is accelerating as the year progresses, with 899,000 beneficiaries getting the discounts through the end of June.
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.